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TRACK 1: DECISION SUPPORT
SYSTEMS AND MODELS
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MONTE CARLO SIMULATION IN 
HEALTHCARE MODELS
Richter A, Mauskopf JA
Research Triangle Institute, Research Triangle Park, NC, US
In this workshop we will focus on Monte Carlo disease
simulations and how they can be used to perform economic
evaluations of healthcare interventions. Monte Carlo dis-
ease simulation is a modeling technique that operates on a
patient level basis, explicitly estimating the effect of vari-
ability among patients in both underlying disease progres-
sion patterns and in individual responsiveness to treat-
ments. Typical outputs from these simulations are patient
functional status, life-years, quality-adjusted life-years, and
associated costs, all of which can be appropriately dis-
counted. The output information is presented in the form of
distributions, which can be used to estimate mean or me-
dian values and confidence intervals for the outcomes of in-
terest. These results can then be used to compute cost-effec-
tiveness ratios and other drug value measures. Monte Carlo
disease simulation also allows decision-makers to address
the question of risk that is associated with smaller popula-
tions who may not tend to the “average” results generated
by Markov models or simulations of large populations. In
this workshop we describe how to create a Monte Carlo
simulation model and how different types of uncertainty
can be incorporated into the model. We will develop a basic
Monte Carlo simulation of HIV/AIDS in @Risk showing
the step-by-step creation of the model. We will run the sim-
ulation and show the typical outcomes that can easily be
tracked by this type of simulation. This workshop should
be beneficial to outcomes researchers and healthcare deci-
sion-makers who need to incorporate uncertainty about the
natural history of a disease and the impact of alternative
disease management strategies for individual patients into
their drug value analyses.
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The model was developed to describe and simulate the nat-
ural history of Alzheimer’s Disease over a 2-year period,
using an innovative decision database methodology. The
decision database models the path-dependent nature of
Alzheimer’s Disease, whereby a patient’s disease outcome
is dependent on the specific secondary conditions experi-
enced. The decision model tracks several aspects of Alz-
heimer’s Disease: participation in an intervention program,
disease stage, side effects, secondary conditions, clinical
complications, institutionalization, and disease progres-
sion. This model reports the number and percent of pa-
tients experiencing disease outcomes and the total direct
and indirect costs associated with treating those patients.
The decision database methodology overcomes the “mem-
ory-less” limitation of Markov-based models, the extensive
time requirement of Monte Carlo models, and the inability
of decision tree software to deal with large, complex mod-
els. The workshop is designed to provide an overview of
the decision database methodology and will focus on the
capability of the methodology to analyze the path-depen-
dent nature of Alzheimer’s Disease. The workshop will
also describe the model development process, including
identification of relevant parameters, model structure, data
sources, and application software. In addition, the work-
shop will demonstrate the decision database software’s
ability to create customized user interfaces and reports.
The decision database methodology enables researchers to
examine clinical and economic aspects of Alzheimer’s Dis-
ease, using a rigorous, probabilistic tool that is able to ana-
lyze the interaction and path-dependent nature of disease
variables. This methodology can be applied to the study of
other diseases.
Contributed Workshop Presentations
